A disruptive billionaire with a yen for innovation herds top researchers into a neoantigen cancer coalition
One of the hottest fields in cancer research that’s been breeding a slew of startups now has its own collaborative effort underway to help investigators march forward at a faster and more certain pace.
The field is neoantigens, and the collaborative is the latest brainchild of The Parker Institute for Cancer Immunotherapy and its partners at the Cancer Research Institute. Dubbed TESLA, for Tumor neoantigEn SeLection Alliance (a twist on acronyms), the coalition will bring together academic and industry researchers who will use their own, individual algorithms to spot the unique neoantigens that appear on individual patients’ cancer cells in order to develop a personalized cell therapy specifically for that individual.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.